Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ascabiol
- Development stage
- Unknown
- Lead developer
- FRiLAB
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Ascabiol** is a topical fixed-dose ectoparasiticide marketed by FRiLAB for **common scabies** and **autumnal trombiculosis** caused by chigger mites. The FRiLAB formulation is a 125 mL lotion containing **benzyl benzoate 10 g/100 mL** and **sulfiram 2 g/100 mL**. It is applied to the skin as a scabicidal and acaricidal treatment intended to eliminate mite infestations. ([frilab.ch](https://frilab.ch/en/product/ascabiol/))
- Brand names
- Ascabiol
- Other names
- benzyl benzoate + sulfiram
02
Targets
PXR (Pregnane X receptor)
Beyond the preview
Go deeper on Ascabiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascabiol.